The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Parietaria

  • Cross-reactivity between the major Parietaria allergen and rotavirus VP4 protein [1].
  • We selected patients with proved atopy to Parietaria but without clinical and endoscopic signs of gastric disease, and we tested them with the specific inhalant allergen during IPEC, recording gastric macroscopic reaction and mucosal mast-cell changes in biopsy specimens [2].
  • Finally, the percentage of cells with fragmented DNA was lower in cultures stimulated with Der p or Parietaria than in those stimulated with tetanus toxoid or C. albicans, and the presence of fenoterol did not modify cell apoptosis (p > 0.05; each comparison) [3].
  • A comparison of the date of birth of 1501 adult patients with severe seasonal respiratory allergy (allergic rhinitis or bronchial asthma) due to parietaria, olive, and grass pollens with the expected births within 2,020,420 births in South Greece during the same period, was performed [4].
  • Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season [5].

High impact information on Parietaria

  • Here we show that the same strategy can be applied to peptides derived from a pollen protein, the major allergen of Parietaria judaica(Par j1), a plant responsible for most allergenic sensitization in the southern Mediterranean area [6].
  • The cytoskeletal protein profilin and a 2-EF-hand calcium-binding allergen were identified as cross-reactive Parietaria allergens, which were recognized preferentially by Parietaria -positive, non-Mediterranean weed pollen-allergic patients [7].
  • Onset of allergic rhinitis was associated with sensitization to birch (odds ratio [OR] = 6.5), Parietaria (OR = 7.4); and pets (OR = 3.0) and with female sex (OR = 1.9) [8].
  • In summer, LAR to Parietaria was significantly more severe than in winter [9].
  • Spectroscopic evidence indicates that haemolytic complement consumption by the Parietaria allergens and their enzymic fragments is most likely related to post-translational side-chains comprising flavonoid derivatives [10].

Biological context of Parietaria

  • IgG antibody response to the inhalant allergen Parietaria judaica (Pj) and IgG subclass distribution were studied in 82 normal subjects, divided into three groups according to age (0-1, 1-20, and 20-60 years) and in 32 allergic subjects aged 20-60 years [11].
  • These results demonstrate that HLA-DRB1*, or genes in linkage disequilibrium, contributes to susceptibility to Parietaria allergy and that total IgE levels can discriminate population subsets where different alleles (at the HLA region or at loci in linkage disequilibrium) contribute to control allergen-specific IgE synthesis [12].

Anatomical context of Parietaria


Associations of Parietaria with chemical compounds

  • These adsorbed and/or peptide-bound tannin-like structures may also explain the exceptional stability of the high- and low-molecular mass allergenic components in Parietaria pollen extracts [10].
  • Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts [16].
  • OBJECTIVE: The aim of this study was to investigate the role of capsaicin-sensitive sensory C-fibres and tachykinins in rabbits sensitized to the major allergen of Parietaria judaica pollen (Par j1) [13].
  • METHODS: Twenty patients, sensitized to grass and/or Parietaria pollen, were subdivided into two groups, one receiving loratadine the other cetirizine respectively [17].
  • Cross-reactivity between the different components in Parietaria judaica pollen extract has been investigated by polyclonal as well as monoclonal antibodies before and after chemical deglycosylation obtained by trifluoromethanesulphonic acid (TFMS) treatment of the extract [18].

Gene context of Parietaria

  • HLA-DRB1* and allergy to Parietaria: linkage and association analyses [12].
  • METHODS: We conducted a double-blind, placebo-controlled, parallel-group study in patients who had a history of allergic rhinitis in response to pollens of grass and Parietaria species and were living in northern Italy [19].
  • Two cDNA clones named P9* and P1* of 794 and 631 bp, respectively, were isolated from a lambda ZAP cDNA expression library using Parietaria judaica (Pj) pollen-specific IgE antibodies from a pool of sera (n = 23) of patients allergic to Pj [20].
  • OBJECTIVE: The possible effectiveness of loratadine in the treatment of allergic cough was assessed in 20 patients with allergic rhinoconjunctivitis and cough due to Parietaria judaica during the pollen season (April to July 1993) [21].
  • On the other hand, FMLP could induce EOS chemotactic activity only in Parietaria-allergic patients, the highest value being registered during the height of the Parietaria season [22].

Analytical, diagnostic and therapeutic context of Parietaria

  • A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen [23].
  • Quantitation of the major allergen of several Parietaria pollens by an anti-Par 1 monoclonal antibody-based ELISA. Analysis of crossreactivity among purified Par j 1, Par o 1 and Par m 1 allergens [24].
  • Linkage was detected with Parietaria skin test positivity (p < (0.01), presence of IgG and IgE antibodies specific for the major allergen Par o 1 (p < 0.020 and p < 0.025, respectively), and absence of Par o 1-specific IgE (p < 0.020) [12].
  • METHODS: Thirty children with asthma solely due to Parietaria who participated in a previous randomized, placebo-controlled trial with SLIT were studied: pulmonary function test and methacholine challenge were carried out at baseline in winter 1999 (out season), during the 1999 season (before randomization), and during the 2001 season [25].
  • OBJECTIVE: The protective effect of oxatomide on inflammatory changes that follow allergen-specific conjunctival challenge was assessed in 20 patients with rhinoconjunctivitis due to Parietaria judaica in a double-blind study [26].


  1. Cross-reactivity between the major Parietaria allergen and rotavirus VP4 protein. di Somma, C., Fiore, L., Di Lonardo, A., Ridolfi, B., Garzillo, C., Chersi, A., Buono, C., Menna, T., Ruffilli, A. Allergy (2003) [Pubmed]
  2. Gastric mucosal mast cells in atopic subjects. Bagnato, G.F., Di Cesare, E., Caruso, R.A., Gulli, S., Cugliari, A., Morabito Lo Prete, A., Previti, M., Muscarà, M., Bottari, M. Allergy (1995) [Pubmed]
  3. Inhibitory activity of fenoterol on Dermatophagoides-, Parietaria-, tetanus-toxoid-, and Candida albicans-stimulated blood mononuclear cells: differences in beta2-adrenoreceptor stimulation but not in cell apoptosis. Silvestri, M., Oddera, S., Scarso, L., Pistoia, V., Tasso, P., Rossi, G.A. The Journal of asthma : official journal of the Association for the Care of Asthma. (2000) [Pubmed]
  4. Is month of birth a risk factor for subsequent development of pollen allergy in adults? Vovolis, V., Grigoreas, C., Galatas, I., Vourdas, D. Allergy and asthma proceedings : the official journal of regional and state allergy societies. (1999) [Pubmed]
  5. Serum levels of soluble CD23 in patients with asthma or rhinitis monosensitive to Parietaria. Its relation to total serum IgE levels and eosinophil cationic protein during and out of the pollen season. Di Lorenzo, G., Drago, A., Pellitteri, M.E., Candore, G., Colombo, A., Potestio, M., Di Salvo, A., Mansueto, S., Caruso, C. Allergy and asthma proceedings : the official journal of regional and state allergy societies. (1999) [Pubmed]
  6. Use of antagonist peptides to inhibit in vitro T cell responses to Par j1, the major allergen of Parietaria judaica pollen. De Palma, R., Wu, S., Sallusto, F., Di Felice, G., Martucci, P., Geraci, D., Colombo, P., Troise, C., Sacerdoti, G., Nocera, A., Gorski, J. J. Immunol. (1999) [Pubmed]
  7. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. Stumvoll, S., Westritschnig, K., Lidholm, J., Spitzauer, S., Colombo, P., Duro, G., Kraft, D., Geraci, D., Valenta, R. J. Allergy Clin. Immunol. (2003) [Pubmed]
  8. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Plaschke, P.P., Janson, C., Norrman, E., Björnsson, E., Ellbjär, S., Järvholm, B. Am. J. Respir. Crit. Care Med. (2000) [Pubmed]
  9. Late asthmatic reaction to perennial and seasonal allergens. Crimi, E., Gianiorio, P., Orengo, G., Voltolini, S., Crimi, P., Brusasco, V. J. Allergy Clin. Immunol. (1990) [Pubmed]
  10. Haemolytic complement consumption by Parietaria pollen extracts in relation to peptide-bound flavonoids. Berrens, L., de la Cuadra López, B. Cell. Mol. Life Sci. (1997) [Pubmed]
  11. IgG subclass antibodies against Parietaria judaica in normal and allergic subjects. Palumbo, S., Di Felice, G., Mari, A., Bonini, S., Bruno, G., Tinghino, R., Afferni, C., Sallusto, F., Pini, C. Allergy (1994) [Pubmed]
  12. HLA-DRB1* and allergy to Parietaria: linkage and association analyses. D'Amato, M., Picardi, A., Menna, T., Di Somma, C., Ariano, R., di Pietro, A., Charron, D., Maggi, E., Matricardi, P., Plebani, A., Poto, S., Testa, G., Sacerdoti, G., Ruffilli, A. Hum. Immunol. (1999) [Pubmed]
  13. The involvement of sensory neuropeptides in airway hyper-responsiveness in rabbits sensitized and challenged to Parietaria judaica. D'Agostino, B., Advenier, C., de Palma, R., Gallelli, L., Marrocco, G., Abbate, G.F., Rossi, F. Clin. Exp. Allergy (2002) [Pubmed]
  14. Immunotherapy and mast cell activation. Carlos, A.G., Carlos, M.L., Santos, M.A., Pedro, E., Santos, S., Lopes-Pregal, A. Allergie et immunologie. (1998) [Pubmed]
  15. Specific immune response to Phleum pratense plant profilin in atopic patients and control subjects. Benítez, D., García-Ortega, P., Picado, C., Milà, J., Vives, J., Martínez, J., Vilella, R. Allergologia et immunopathologia. (2001) [Pubmed]
  16. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Ibarrola, I., Sanz, M.L., Gamboa, P.M., Mir, A., Benahmed, D., Ferrer, A., Arilla, M.C., Martínez, A., Asturias, J.A. Clin. Exp. Allergy (2004) [Pubmed]
  17. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Ciprandi, G., Pronzato, C., Ricca, V., Passalacqua, G., Danzig, M., Canonica, G.W. Clin. Exp. Allergy (1997) [Pubmed]
  18. Role of carbohydrate moieties in cross-reactivity between different components of Parietaria judaica pollen extract. Mucci, N., Liberatore, P., Federico, R., Forlani, F., Di Felice, G., Afferni, C., Tinghino, R., De Cesare, F., Pini, C. Allergy (1992) [Pubmed]
  19. Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. Foresi, A., Pelucchi, A., Gherson, G., Mastropasqua, B., Chiapparino, A., Testi, R. J. Allergy Clin. Immunol. (1996) [Pubmed]
  20. Isolation and characterization of two cDNA clones coding for isoforms of the Parietaria judaica major allergen Par j 1.0101. Duro, G., Colombo, P., Assunta Costa, M., Izzo, V., Porcasi, R., Di Fiore, R., Locorotondo, G., Cocchiara, R., Geraci, D. Int. Arch. Allergy Immunol. (1997) [Pubmed]
  21. Loratadine in the treatment of cough associated with allergic rhinoconjunctivitis. Ciprandi, G., Buscaglia, S., Catrullo, A., Marchesi, E., Bianchi, B., Canonica, G.W. Ann. Allergy Asthma Immunol. (1995) [Pubmed]
  22. Allergic bronchial asthma: eosinophil chemotaxis and antihistaminic drug modulation. Ventura, M.T., Casale, G., Cenci, L., Tursi, A. Allergy (1996) [Pubmed]
  23. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. D'Amato, G., Lobefalo, G., Liccardi, G., Cazzola, M. Clin. Exp. Allergy (1995) [Pubmed]
  24. Quantitation of the major allergen of several Parietaria pollens by an anti-Par 1 monoclonal antibody-based ELISA. Analysis of crossreactivity among purified Par j 1, Par o 1 and Par m 1 allergens. Ayuso, R., Carreira, J., Polo, F. Clin. Exp. Allergy (1995) [Pubmed]
  25. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. Pajno, G.B., Passalacqua, G., Vita, D., Caminiti, L., Parmiani, S., Barberio, G. Allergy (2004) [Pubmed]
  26. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ciprandi, G., Buscaglia, S., Pronzato, C., Benvenuti, C., Cavalli, E., Bruzzone, F., Canonica, G.W. Ann. Allergy Asthma Immunol. (1995) [Pubmed]
WikiGenes - Universities